For veterinarians and livestock producers, a custom vaccine isn’t an extravagance, but rather another tool in the box for addressing new or uncommon strains of livestock pathogens.
Researchers at the University of Hawaii medical school have successfully developed a vaccine candidate for the Zika virus, showing that it is effective in protecting both mice and monkeys from the infection.
Researchers compared the detection frequency of avian influenza H7 subtypes at live poultry markets in Guangdong Province, China, before and after the introduction of a bivalent H5/H7 vaccine in poultry. The vaccine was associated with a 92 percent reduction in H7 positivity rates among poultry and a 98 percent reduction in human H7N9 cases.
The Ministry of Health of the Democratic Republic of the Congo (DRC) announced, November 26, that a randomized control trial has begun to evaluate the effectiveness and safety of drugs used in the treatment of Ebola patients. The trial will form part of a multi-outbreak, multi-country study that was agreed to by partners under a World Health Organization (WHO) initiative.
Health officials are preparing to launch a clinical trial designed to test whether experimental Ebola therapies improve patients’ chances of survival in the outbreak in the Democratic Republic of the Congo.
Researchers had a recent breakthrough toward creating a better Salmonella vaccine, by understanding how memory T cells could provide better protection against Salmonella infection.
Uganda will become the first country in the world to give the vaccine against Ebola without experiencing an active outbreak.
Yellow fever vaccine dosed at one-fifth the usual level during a major African outbreak appeared to provide adequate protection to nearly all recipients for a full year.
A newly-developed vaccine against swine influenza is being launched in the UK. The vaccine, Respiporc FLUpanH1N1, protects against the pandemic strain of flu pdmH1N1(2009) which is particularly prevalent in the British Isles.
The Walter Reed Army Institute of Research, or WRAIR, began a phase 1 clinical trial to evaluate the safety and tolerability of two different doses of a Marburg vaccine candidate in humans and determine if the vaccine generates enough antibodies and T-cell responses to the Marburg virus.